ADMEcell is a biotechnology startup that crafts innovative and comprehensive solutions for therapeutic modeling and in vitro re-profiling with ready-to-use cell-based and ELISA-based assay kits. Established in 2008, the company develops, manufactures, and supplies ready-to-use solutions for therapeutic modeling and in vitro re-profiling. Their offerings include a range of ready-to-use cell-based assays such as the Cacoready kit and the Ready Port-MDR1 kit. Additionally, they provide ELISA-based assays including the Fastelysa Human Immunoglobulin G Quantification Kit and the Fastelysa Mouse Immunoglobulin Isotyping Kit.
ADMEcell operates within the biotechnology, manufacturing, and pharmaceutical industries, positioning itself as a key player in the development of advanced solutions for drug discovery and development. Although specific details regarding their headquarters and recent investment rounds are not available, the company's commitment to providing innovative solutions in the field of therapeutic modeling and in vitro re-profiling certainly positions them as an attractive prospect for potential venture capital investment.
